ESMO 2017 | Can the efficacy of one drug be influenced by another?
Michael Atkins, MD, from the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discusses drug combinations in the treatment of melanoma at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The ECOG-AGRIN 6134 study (NCT02224781) investigated dabrafenib plus trametinib followed by ipilimumab plus nivlumab, and vice versa. This study will determine whether the efficacy of one treatment is influenced by another. Studies looking at other aspects of this combination are also being carried out.
Get great new content delivered to your inboxSign up